共 50 条
- [31] A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrugEJC SUPPLEMENTS, 2008, 6 (12): : 129 - 130Weiss, G. J.Infante, J. R.Borad, M.Langmuir, V. K.Kroll, S.Jung, D.Tibes, R.Chiorean, E. G.Jones, S. F.Burris, H. A.
- [32] A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue SarcomaONCOLOGY, 2011, 80 (1-2) : 50 - 56Ganjoo, Kristen N.Cranmer, Lee D.Butrynski, James E.Rushing, DanielAdkins, DouglasOkuno, Scott H.Lorente, GustavoKroll, StewLangmuir, Virginia K.Chawla, Sant P.
- [33] Final results of a phase I trial of PR104, a pre-prodrug of the bioreductive prodrug PR104 A, given weekly to solid tumor patientsJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)McKeage, M. J.Gu, Y.Wilson, W. R.Hill, A.Amies, K.Melink, T. J.Jameson, M. B.
- [34] Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Yi, Cecilia Ysabel AranaBorthakur, GautamThall, Peter F.Coveler, Andrew L.Ravandi, FarhadJabbour, EliasFaderl, StefanThomas, Deborah A.Cortes, Jorge E.Kadia, Tapan M.Kornblau, Steven MitchellDaver, Naval GuastadPemmaraju, NaveenNguyen, Hoang Q.Wilson, William R.Melink, Teresa J.Gutheil, JohnKantarjian, Hagop M.Estey, ElihuKonopleva, Marina
- [35] Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid MalignanciesCLINICAL CANCER RESEARCH, 2011, 17 (09) : 2997 - 3004Weiss, Glen J.Infante, Jeffrey R.Chiorean, E. GabrielaBorad, Mitesh J.Bendell, Johanna C.Molina, Julian R.Tibes, RaoulRamanathan, Ramesh K.Lewandowski, KarenJones, Suzanne F.Lacouture, Mario E.Langmuir, Virginia K.Lee, HankKroll, StewBurris, Howard A., III
- [36] A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaCLINICAL CANCER RESEARCH, 2019, 25 (02) : 478 - 486Laubach, Jacob P.Liu, Chia-JenRaje, Noopur S.Yee, Andrew J.Armand, PhilippeSchlossman, Robert L.Rosenblatt, JacalynHedlund, JacquelynMartin, MichaelReynolds, CraigShain, Kenneth H.Zackon, IraStampleman, LauraHenrick, PatrickRivotto, BradleyHornburg, Kalvis T., VDumke, Henry J.Chuma, StaceySavell, AlexandraHandisides, Damian R.Kroll, StewAnderson, Kenneth C.Richardson, Paul G.Ghobrial, Irene M.
- [37] PHARMACODYNAMIC BIOMARKER ASSESSMENTS IN A PHASE I/II TRIAL OF THE HYPOXIA-ACTIVATED PRODRUG TH-302 AND BEVACIZUMAB IN BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMANEURO-ONCOLOGY, 2014, 16Cavazos, DavidGruslova, AleksandraSun, J.Floyd, John R.Fichtel, LisaTadi, SurendarLodi, AlessiaTiziani, StefanoHart, C. P.Eng, ClarenceBrenner, Andrew
- [38] Japanese phase I trial of hypoxia-activated prodrug evofosfamide (TH-302) as monotherapy in patients with solid tumors or in combination with gemcitabine in patients with advanced pancreatic cancerEUROPEAN JOURNAL OF CANCER, 2015, 51 : S436 - S436Mitsunaga, S.Takahashi, H.Doi, T.Johne, A.Wang, J.Shimizu, A.Ikeda, M.
- [39] Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trialCancer Chemotherapy and Pharmacology, 1997, 40 : 189 - 201Janet MartinStephen M. StribblingGrace K. PoonRichard H. J. BegentMark NapierSurinder K. SharmaC. J. Springer
- [40] Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trialCANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (03) : 189 - 201Martin, JStribbling, SMPoon, GKBegent, RHJNapier, MSharma, SKSpringer, CJ